WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597137
CAS#: 1207181-29-0 (F18)
Description: Piflufolastat-F18, also known as Dcfpyl F-18 is a PET imaging agent for prostate-specific membrane antigen.
Hodoodo Cat#: H597137
Name: Piflufolastat-F18
CAS#: 1207181-29-0 (F18)
Chemical Formula: C18H2318FN4O8
Exact Mass: 441.15
Molecular Weight: 441.400
Elemental Analysis: C, 48.98; H, 5.25; F, 4.08; N, 12.69; O, 29.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1207181-29-0 (F18) 1423758-00-2 (F-19)
Synonym: Dcfpyl F-18; 18F-DCFPyL; Piflufolastat-F18
IUPAC/Chemical Name: (((S)-1-carboxy-5-(6-(fluoro-18F)nicotinamido)pentyl)carbamoyl)-L-glutamic acid
InChi Key: OLWVRJUNLXQDSP-MVBOSPHXSA-N
InChi Code: InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
SMILES Code: O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC(C1=CC=C([18F])N=C1)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 441.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Bouvet V, Wuest M, Bailey JJ, Bergman C, Janzen N, Valliant JF, Wuest F. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. Mol Imaging Biol. 2017 Dec;19(6):923-932. doi: 10.1007/s11307-017-1102-x. PubMed PMID: 28639122.
2: Basuli F, Zhang X, Woodroofe CC, Jagoda EM, Choyke PL, Swenson RE. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. J Labelled Comp Radiopharm. 2017 Mar;60(3):168-175. doi: 10.1002/jlcr.3487. Epub 2017 Feb 1. PubMed PMID: 27990672; PubMed Central PMCID: PMC5344719.
3: Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26. PubMed PMID: 27889802; PubMed Central PMCID: PMC5323462.
4: Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Ponnala S, Babich JW. Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15. PubMed PMID: 27847991; PubMed Central PMCID: PMC5323493.
5: Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0. PubMed PMID: 26013479; PubMed Central PMCID: PMC4493776.